Related Experiment Video
Updated: Jul 23, 2026

Activation of Apoptosis by Cytoplasmic Microinjection of Cytochrome c
Published on: June 29, 2011
c-Myc is able to sensitize human melanoma cells to diverse apoptotic triggers
Lucy T C Peltenburg1, Elza C de Bruin, Dorothea Meersma
1Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands. peltenburg@lumc.nl
Abstract:
Compared with other types of tumours, malignant melanomas are highly refractory to radio- or chemotherapy. To support the search for possible sensitizers, we explored the effects of the cellular oncoproteins c-Myc and N-Ras, which can decrease the clonogenic potential of irradiated p53-negative IGR39D melanoma cells. Using stable transfectants of this cell line, we showed that mutant N-Ras decreased the proliferation rate by inducing a prolonged cell cycle arrest. In contrast, c-Myc made these melanoma cells more prone to radiation-induced cell death. Membrane blebbing, the formation of apoptotic bodies and caspase activation, as measured by cleavage of Asp-Glu-Val-Asp (DEVD) substrate and poly(ADP-ribose) polymerase (PARP), indicate that these cells die by an apoptotic process. c-Myc also sensitized these p53-deficient melanoma cells to treatment with various cytotoxic drugs and heat shock. Similar results were obtained in inducible c-Myc models of IGR39D and in another melanoma cell line, 9007, which expresses functional p53. Together, these findings indicate that c-Myc is capable of sensitizing typically resistant tumour cells and that this occurs irrespective of the functional status of the p53 protein. Our results should facilitate the identification of factors that can be exploited for the treatment of aggressive cancers.
Insights
The cellular oncoprotein c-Myc sensitizes radioresistant melanoma cells to cancer therapies, regardless of p53 status. This finding aids in developing treatments for aggressive cancers by identifying novel sensitizing factors.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Malignant melanomas exhibit high resistance to conventional radio- and chemotherapy.
- Identifying sensitizing agents is crucial for improving melanoma treatment efficacy.
Purpose of the Study:
- To investigate the role of cellular oncoproteins c-Myc and N-Ras in sensitizing melanoma cells to cancer therapies.
- To determine if c-Myc-mediated sensitization is dependent on p53 protein status.
Main Methods:
- Stable transfection of p53-negative IGR39D melanoma cells with c-Myc and N-Ras.
- Assessment of proliferation rates, cell cycle arrest, and apoptosis (caspase activation, PARP cleavage).
- Evaluation of sensitization to radiation, cytotoxic drugs, and heat shock in p53-deficient and p53-functional melanoma cells.
Main Results:
- Mutant N-Ras reduced proliferation via cell cycle arrest.
- c-Myc induced apoptosis and sensitized p53-negative melanoma cells to radiation, chemotherapy, and heat shock.
- Similar sensitization effects of c-Myc were observed in p53-functional melanoma cells.
Conclusions:
- c-Myc effectively sensitizes typically resistant melanoma cells to various cancer treatments.
- This sensitization mechanism is independent of the p53 protein's functional status.
- The findings support the development of c-Myc-based strategies for treating aggressive cancers.
More Related Videos
09:57Real Time Detection of In Vitro Tumor Cell Apoptosis Induced by CD8+ T Cells to Study Immune Suppressive Functions of Tumor-infiltrating Myeloid Cells
Published on: January 29, 2019
06:09Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Related Concept Videos
Abnormal Proliferation
Apoptosis
The Extrinsic Apoptotic Pathway
The Intrinsic Apoptotic Pathway
Induced Pluripotent Stem Cells
Somatic cells are...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...